Research and Markets: A Brief Report on the Development of Syk Kinase Inhibitors Including a Summary List of the Target Pipeline with Other Research Projects.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/540dc3/brief_report_syk) has announced the addition of the "Brief Report: Syk Kinase Inhibitors" report to their offering. The present Brief Report about small molecules and small interfering RNA Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, are a class of 20-25 nucleotide-long double-stranded RNA molecules that play a variety of roles in biology. (siRNA) targeting spleen tyrosine kinase tyrosine kinase An enzyme intimately linked to signal transduction–ST, either as a receptor-type TK, which participates in transmembrane signaling, or as an intracellular TK, participating in ST to the nucleus; ↑ or ↓ TK activity is associated with (syk) provides a competitor analysis of these anti-inflammatory molecules. R&D projects of syk kinase inhibitors to treat rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. , immune thrombocytopenic purpura immune thrombocytopenic purpura n. See idiopathic thrombocytopenic purpura. immune thrombocytopenic purpura Idiopathic thrombocytopenic purpura, see there (ITP ITP - Intent to Package ), asthma, allergic rhinitis Allergic Rhinitis Definition Allergic rhinitis, more commonly referred to as hay fever, is an inflammation of the nasal passages caused by allergic reaction to airborne substances. and B-cell lymphoma are discussed as of February 2008. Clinical proof of concept has been achieved in two indications for syk kinase inhibitors, results of the clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy in further indications is pending. The brief report with 14 pages describes the background of the target and the scientific rationale to develop molecules targeting syk kinase. The target is suitable for various inflammatory indications and hematologic malignancies. The status of clinical and preclinical R&D is described and critically assessed. Individual profiles of molecules already in clinical development and to reach clinical development soon are presented in an executive summary with references. The Brief Report also includes a summary list of the target pipeline with other research projects. The Target Pipeline Summary presents a list in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Therapeutic Area - Company - Indication - R&D Stage Key Topics Covered: - Target and Scientific Rationale - Asthma and allergic rhinitis - Immune Thrombocytopenic Purpura (ITP) - Rheumatoid arthritis - B cell lymphoma - Status of Development and Assessment - Individual Project Profiles - Target Pipeline Summary For more information visit http://www.researchandmarkets.com/research/540dc3/brief_report_syk |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion